Brokerages Set Hims & Hers Health, Inc. (NYSE:HIMS) PT at $25.13

Hims & Hers Health, Inc. (NYSE:HIMS) has earned a consensus rating of “Hold” from the seventeen ratings firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $25.13.

A number of equities analysts have recently commented on HIMS shares. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Piper Sandler boosted their price objective on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Needham & Company LLC upped their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 6th. Finally, Morgan Stanley initiated coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective for the company.

Hims & Hers Health Trading Up 5.1 %

HIMS opened at $44.70 on Tuesday. Hims & Hers Health has a 12 month low of $9.14 and a 12 month high of $46.01. The stock has a 50-day moving average of $30.50 and a 200 day moving average of $23.43. The firm has a market cap of $9.77 billion, a P/E ratio of 101.60 and a beta of 1.35.

Insiders Place Their Bets

In related news, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the transaction, the insider now owns 184,947 shares of the company’s stock, valued at $6,206,821.32. The trade was a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 142,886 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98. Following the sale, the chief financial officer now directly owns 112,186 shares in the company, valued at $3,357,726.98. This trade represents a 56.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,167,913 shares of company stock worth $34,303,787. 17.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in HIMS. Crewe Advisors LLC purchased a new position in Hims & Hers Health in the fourth quarter valued at about $28,000. Raleigh Capital Management Inc. grew its position in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the last quarter. Blume Capital Management Inc. raised its stake in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, US Bancorp DE boosted its stake in Hims & Hers Health by 346.7% in the fourth quarter. US Bancorp DE now owns 1,943 shares of the company’s stock valued at $47,000 after acquiring an additional 1,508 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.